Shares of e-tail powerhouse Amazon.com, Inc. (NASDAQ:AMZN) are inching their way higher this morning, last seen up 0.3% at $2,016.94, as the company's annual Prime Day event kicks off. While the 48-hour sale for Amazon's Prime members is attracting its usual bout of attention, the FAANG stock is catching the eye of analysts.

Specifically, Loop Capital reiterated its "buy" rating and $2,380 price target, saying the event delivers three purposes: to generate significant volume during a slow sales period, increase Prime subscriptions, and create free advertising for AMZN. Meanwhile, Cowen waxed optimistic on Amazon's upcoming second-quarter results, labeling its valuation "attractive."

Jefferies echoed this upbeat take, saying a "key differentiator for AMZN will be its new one-day shipping initiative. Coming into today, all but one of 28 covering analysts carried a "buy" or "strong buy" rating on Amazon stock. 

Looking into options, data from the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows the security with a 10-day call/put volume ratio of 1.33, ranking in the 93rd percentile of its annual range. In other words, calls have been bought to open over puts at a faster-than-usual clip.

Further, Amazon stock's short-term options are attractively priced at the moment. This is per the security's Schaeffer's Volatility Index (SVI) of 26%, which ranks in just the 23rd percentile of its annual range. In other words, near-term AMZN options are pricing in relatively modest volatility expectations.

On the charts, Amazon stock has been climbing, inching its way toward fresh record highs. Just last week the stock touched a 10-month peak of $2,035.80, a chip-shot away from the e-tailer's September 2018 record high of $2,050.50. Year-to-date, the powerhouse has tacked on just almost 34%

The shares of Avrobio Inc (NASDAQ:AVRO) are popping today after the drugmaker announced positive data from its clinical trials of its investigational gene therapy drug AVR-RD-01 in patients with Fabry Disease, as well as an 87% substrate reduction in its first post-treatment kidney biopsy. AVRO is up 7.1% at $15.29 in response.

Since spiking at $28.52 in early April, AVRO has suffered a gradual descent on the charts. While the $13 region has caught the stock on multiple occasions, pressure at its 50-day and 40-day moving averages just stifled its most recent rally attempt. Now, Avrobio is trading back north of its 40-day trendline, and is threatening to conquer its 50-day, too. 

Despite it's recent behavior, analysts have been incredibly optimistic on the security, with eight in coverage giving it a "buy" or better rating, and only one saying "hold." What's more, the consensus 12-month target price of $36.50 is at a 59.2% premium to last Friday's close, and represents an area AVRO hasn't reached in nearly two years. 

Shorts have started to rapidly unwind, too, down over 30% in the last two reporting periods to 670,705 shares -- the lowest volume since last February. These bearish bets cover only 2.9% of the stock's available float. However, it would take nearly a week to cover these pessimistic positions at AVRO's average pace of trading, which could mean there's potential for a short squeeze. 

One trading day removed from a nasty bear gap, Aurora Cannabis Inc (NYSE:ACB) is attempting a rebound this morning, last seen up 2% to trade at $6.93. This overdue lift comes after the weed company inked growing operations licenses from Health Canada for two outdoor cultivation sites. 

Aurora Cannabis stock is fresh off its worst week of 2019. The $7 level, an area that had served as a floor the last three months, has now emerged as possible resistance. Still, ACB is sporting a year-to-date lead of 36% and its 14-day Relative Strength Index (RSI) sits at 28 -- suggesting the shares are oversold and could be due to rebound.

Analysts have remained undeterred by the security's recent slide. Of the seven analysts covering ACB, five rate it a "buy" or better, with zero "sells" on the books. Short sellers though, have continued to pile on. Short interest increased by 4.5% in the two most recent reporting periods, to 85.93 million shares, the most since mid May.

In the options pits, calls have reigned supreme. ACB's 10-day put/call volume ratio of 6.01 on the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) means that six calls have been traded for every put in the last 10 days.

Whatever the motive, now is the time to pursue options on the weed stock. Its Schaeffer's Volatility Index (SVI) of 50% ranks in the 28th annual percentile, indicating short-term options are pricing in relatively low volatility expectations at the moment.

The shares of Tiffany & Co. (NYSE:TIF) and L Brands Inc (NYSE:LB) are trading in the red this morning due to bearish analyst attention at Citigroup. Let's take a quick look at the bear note and how TIF and LB stocks are trading.

For TIF, Citi downgraded its opinion to "neutral" from "buy" and cut its price target to $100 from $115. The brokerage firm said it doesn't expect the company's second quarter turnaround to go as planned, even though it faces easy comparables from a year ago.

The equity has opened down 1% at $93.70. Year-over-year, it's down more than 28%, and the 200-day moving average looks set to act as resistance again, like it did in April and May, while the 50-day trendline is also bearing down overhead.

Recent options traders have been betting on more downside, based on data from the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). The 10-day put/call volume ratio there comes in at 1.58, which ranks in the 82nd annual percentile, meaning put buying has been more popular than normal. Also on the sentiment front, other analysts are split on their opinions, with half saying to buy the shares, and the others handing out just "hold" recommendations.

LB stock, meanwhile, is trading down 0.9% at $26.26, after it too was downgraded to "neutral" from "buy," while Citi also cut its price target to $27 from $35. The brokerage firm said it may be too late for the company's struggling Victoria's Secret business to turn itself around.

This bear note comes after L Brands was just rejected by the 200-day moving average, and the stock is now testing its year-to-date breakeven level. Meanwhile, Citi's not the only one growing bearish on the shares, as short interest popped more than 26% in the last two reporting periods. Most other analysts are already bearish on the retailer, with 12 of 17 firms handing out "hold" or "sell" recommendations.

Multiple brokerage firms have just made big calls for the healthcare sector. Three names hit with the equivalent of a "sell" rating today are lab equipment specialist Mettler-Toledo International Inc. (NYSE:MTD), diagnostics services provider Quest Diagnostics Inc (NYSE:DGX), and drugmaker Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Barclays downgraded MTD shares to "underweight" with a $680 price target -- far below the current share price of $818.39. Right now down 2% on the day, Mettler-Toledo is pacing for a fifth straight session in the red, breaking its strong 2019 uptrend. Overall, the equity has a year-to-date lead of almost 45%, yet all other analysts share the view of Barclays.

Specifically, there are eight brokerages in coverage, and they all have "hold" or "strong sell" recommendations. Short interest is also somewhat high, based on the short-interest ratio of 5.90, showing it'd take shorts almost six days to cover, going by average daily trading volumes.

DGX shares were cut to "sell" at Goldman Sachs with a $5 price-target cut to $85. The stock did manage to find support at its 50-day moving average earlier, but still remains almost 13% lower year-over-year. Most analysts are already on the bearish side, with the majority sporting "hold" ratings.

Of note, near-term options traders are unusually call-skewed right now. Quest Diagnostics has a Schaeffer's put/call open interest ratio (SOIR) of 0.29, ranking in the bottom percentile of its annual range, meaning this type of call tilt is extremely rare.

Finally, TEVA stock was cut to "underweight" at Morgan Stanley, which cited the litigation risk around the company for its role in the opioid crisis. The shares have fallen 9% to $8.42, holding near their multi-year lows, and put trading has picked up today, with new positions opening at the September 9 put. 

While the vast majority of analysts have already moved to the sidelines with "hold" or worse ratings, there are still four positive views left, suggesting the streak of bear notes could continue. Meanwhile, short interest keeps rising, up almost 43% in the last two reporting periods.

U.S. stocks have pared their gains after hitting record highs earlier. Three names making moves in the meantime are drugmakers Eton Pharmaceuticals Inc (NASDAQ:ETON) and Capricor Therapeutics Inc (NASDAQ:CAPR), as well as gunfire detection specialist Shotspotter Inc (NASDAQ:SSTI). We'll breakdown how ETON, CAPR, and SSTI shares are trading below.

ETON Crashes on FDA Decision

ETON shares have given back 15.2% today to trade at $7.04 after the company's conjuctivitis treatment failed to win approval from the Food and Drug Administration (FDA). This set up the stock for its lowest close since February, though the $7 area could act as a floor like it did last month. Right now there's just one analyst in coverage, and their 12-month price target is all the way up at $18. ETON stock briefly topped the $10 level in intraday trading back in mid-May.

Capricor Therapeutics Stock More Than Doubles

CAPR is going the other direction today, surging 153% to trade at $8.15. The company announced positive results for its treatment for Duchenne Muscular Dystrophy (DMD) in a mid-stage trial. The huge move higher puts the shares above the 200-day moving average for the first time in over a year, with Capricor now in positive territory for 2019. This time last year, however, the equity was near the $16 mark, which is still below the average analyst price target of $35.

Bear Note Pressures Shotspotter

SSTI shares have moved south out of their recent consolidation area, dropping 8.6% today to $39.47. Pressuring the stock is a note out of Northland Capital, which downgraded Shotspotter to "market perform" and cut its price target to $47 from $60. Northland wrote that it's concerned about potential churn in SSTI's customer base. Today's price action also puts the security below recent support from the 320-day moving average.

As for sentiment data for the stock, 70% of brokerage firms recommend buying it, and the average 12-month price target is $52.88. On the other hand, short interest keeps building, with more than 29% of the float held by short sellers at the moment.

The shares of Domino's Pizza, Inc. (NYSE:DPZ) are trading down 6.6% before the opening bell after the company reported weak second-quarter revenue and same-store sales. If the price action holds, this would put DPZ near the $253 area, right near the year-to-date breakeven level. The move would have them far south of a recent consolidation pattern, and below the 200-day moving average, a trendline the shares haven't close beneath in months.

Technical traders may also want to take note of the $240 region, which served as a floor during the stock's post-earnings bear gap from February. It would seem some bears already got a jump on the sell-off, since DPZ fell 4.3% yesterday.

Speaking of yesterday's trading, there was also heavy action at the July 250 and 260 puts, which now own the no. 1 and no. 3 spots on the security's top open interest positions list, and have helped drive DPZ's Schaeffer's put/call open interest ratio (SOIR) to a put-skewed 1.35. On the call side, the July 310 strike is most popular, where 1,461 contracts reside.

We'll be on the watch for reactions out of the analyst community, even though there haven't been any yet. Right now, most covering analysts have bullish ratings in place, with nine "buy" or "strong buy" recommendations on the books, compared to four "holds" and not a single "sell" rating. 

B. Riley FBR downgraded Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to "sell" from "neutral," and lowered its price target to $1.10 from $1.90 -- a 25% discount to last night's close. In reaction, the penny stock has plunged 4.1% out of the gate to trade at $1.40.

It's already been a tough stretch for the shares of the EpiPen rival, which were down almost 64% year-over-year heading into today's trading. More recently, the stock's rebound off its July 2 record low of $1.20 was quickly contained by familiar resistance at its descending 50-day moving average.

Nevertheless, the majority of the analysts in coverage still maintain a "buy" or better rating on the biopharmaceutical name. Plus, the average 12-month price target sits all the way up at $171.92. More bear notes could be in store for the underperformer.

Elsewhere on the sentiment front, short sellers have been increasing their exposure to the struggling stock. Year-to-date, short interest on ADMP is up 13.4% to 4.08 million shares. This accounts for a healthy 8.7% of the security's available float, or 12.9 times the average daily pace of trading. These bears are sidelined today, though, with the equity on the short-sale restricted list.

One of the worst stocks on the New York Stock Exchange (NYSE) today is Fiat Chrysler Automobiles NV (NYSE:FCAU), down 4.3% to trade at $13.56, after Goldman Sachs weighed in the European automakers, initiating coverage on FCAU with a "sell" rating. The analyst in coverage sees near-term challenges for earnings growth in North America, as well as other headwinds such as trade tensions, Brexit, and carbon dioxide (CO2) emissions targets. 

Today's pullback interrupts what was a nice run on the charts for FCAU this summer. Since bottoming at $12.58 on May 31 amid auto tariff tensions, the shares had added 13% through last night's close, and last week toppled their 200-day moving average. While the auto stock has surrendered this trendline in early trading today, it is still holding above its year-to-date breakeven level. 

Analyst sentiment is pretty evenly skewed for a stock that has shed 23% year-over-year. Of the nine brokerages in coverage, four rate it a "buy" or better, with the other five doling out tepid "holds." As far as the average 12-month price target, it sits all the way up at $20, territory not traded at since June 2018.

In the options pits, puts are the preferred vehicle for trading. FCAU's 10-day put/call volume ratio of 2.52 on the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) ranks in the 95th percentile of its annual range, indicating not only that puts have doubled calls in the past two weeks, but also that the rate of put buying has been much faster than usual.

Options are an intriguing route right now, because the equity has had a tendency to make bigger moves than options traders were pricing in over the past year. The stock's Schaeffer's Volatility Scorecard (SVS) sits at 98 (out of 100), which could make buying premium an even more attractive choice. 

U.S. stocks are flat today, though the Dow managed a fresh record high. Looking at the healthcare sector specifically, three names making big moves are Immuron Limited (NASDAQ:IMRN), Bio-Path Holdings Inc (NASDAQ:BPTH), and CareDx Inc (NASDAQ:CDNA). Here's what to know about the shares of IMRN, BPTH, and CDNA today.

Podcast Mentions Send Consumers to Immuron's Travelan

After jumping roughly 150% earlier, the shares of Australia-based IMRN were last seen 64% higher at $4.81. Sparking the breakout was the company's announcement that podcast mentions helped boost sales of its Travelan product, which is meant to reduce diarrhea and other digestion issues when traveling to foreign countries. Overall, total North American revenue jumped by 52% in the company's fiscal year 2019. On the other hand, the stock has still given back more than half its value in the past year, and hit an all-time low of $2.38 in June.

New "Buy" Rating, Lofty Price Target Lift BPTH

BPTH stock is trading up 17.4% at $15.15, after H.C. Wainwright began coverage with a "buy" recommendation and $28 price target -- a premium of 117% to yesterday's close. The brokerage firm cited confidence in the company's main product, prexigebersen, and Bio-Path's DNAbilize technology. While BPTH is set to settle atop the 50-day moving average for the first time since April, the shares remain stuck in their series of lower highs from recent months, though pullbacks have been contained by the 200-day moving average. There was only one brokerage firm in coverage before today, though it also recommended buying the cancer treatment specialist.

Scathing Short Position Smacks CareDx

CDNA shares, meanwhile, are moving sharply lower, last seen 14.2% below breakeven at $32.01 -- set for their worst session since July 2017. A new short position out of Kerrisdale Capital is responsible for the sell-off, with the firm saying CareDx's diagnostic test AlloSure "is mostly useless, and potentially dangerous if used improperly." Kerrisdale said CareDX will be "in a precarious position, particularly as physicians wise up to the futility of AlloSure," and Medicare coverage will become jeopardized. As such, "the prognosis for [CDNA] stock price is dim."

Despite the huge pullback, the stock remains up 166% year-over-year, having just touched an all-time high of $41.27 on July 11. Looking at the data, Kerrisdale is far from the only CDNA bear. Short interest increased 14% in the last reporting period, and now accounts for 13.7% of the equity's total available float. Today, of course, the stock has landed on the short-sale restricted list.

Nu Skin Enterprises, Inc. (NYSE:NUS) is one of the biggest pre-market losers this morning, last seen 21.9% in the red shortly before the open after the direct selling company made a sizable adjustment to the downside in its full-year forecast. NUS told investors the change is due to a number of factors, most notably weakness in China, but also "media scrutiny" that has hurt its standing with consumers. A few analysts have weighed in on Nu Skin, as well.

Jefferies downgraded its opinion to "hold" from "buy" and cut its price target in half to $40, saying it did not see the announcement coming. D.A. Davidson also lowered its rating to "hold" and moved its price target to $38 from $88, and Stifel gave a price-target cut to $37 from $45. There were already two "sell" or "strong sell" ratings on the stock coming into today.

NUS was down roughly 50% from its August peak just shy of $89, and a breakout attempt back in May quickly disappeared after coming up a few points shy of the 200-day moving average. The shares hit a three-year low of $43.65 just yesterday.

Many bears were prepared for additional losses, based on data from the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). Almost nine puts were bought to open for every call during the past 10 days,and peak open interest is at the September 40 put. Meanwhile, short interest popped 21.5% in the last two reporting periods.

Orion Group Holdings Inc (NYSE:ORN) stock is up 8.7% in electronic trading, after the Texas-based construction concern won a $52 million contract. Specifically, ORN's marine business will provide dredging services for the South Texas Gateway Terminal project, and will provide design assistance for the marine terminal.

Should today's pre-market price action pan out, it would extend ORN stock's impressive rebound off its May 23 record low of $1.31. Through last night's close at $3.78, the shares have nearly tripled, climbing above several long-term moving averages in the process, including their 50-, 80-, and 120-day trendlines. The security could take out its 200-day moving average in today's trading, last seen at $3.91, not toppled on a daily closing basis since last September.

Most analysts are upbeat toward Orion Group, with two-thirds of those in coverage maintaining a "strong buy" rating. Plus, the average 12-month price target of $6.05 is a 60% premium to Tuesday's settlement price. And earlier this month, Noble said the equity is "poised for a strong rebound," and reiterated its "outperform" rating and $7.10 price target.

Elsewhere, shorts have started to cover, with short interest down 2.7% in the most recent reporting period. The 1.82 million shares still sold short accounts for a healthy 6.6% of ORN's available float, or 3.8 time the average daily pace of trading.